NR1I2 and prostate cancer: The vitamin K-2/SXR mechanism was proven to activate expression of AKR1C1 and AKR1C2 in osteoblastic cells [73], but TERE1/K-2-mediated activation of SXR has not been previously studied in prostate cancer.